login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SAB BIOTHERAPEUTICS INC (SABS) Stock News
USA
- NASDAQ:SABS -
US78397T2024
-
Common Stock
3.25
USD
+0.24 (+7.97%)
Last: 10/31/2025, 8:12:51 PM
3.22
USD
-0.03 (-0.92%)
Pre-Market:
11/3/2025, 7:29:56 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SABS Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Benzinga
- Mentions:
PRPH
ABP
WORX
COSM
...
12 Health Care Stocks Moving In Friday's After-Market Session
a month ago - By: Benzinga
- Mentions:
PDEX
IRWD
ENTA
SCYX
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
2 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Highlights Data in Multiple Presentations at EASD
2 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Highlights Data in Multiple Presentations at EASD
2 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
2 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
3 months ago - By: Zacks Investment Research
- Mentions:
ABSI
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
3 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
3 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
4 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Oversubscribed $175 Million Private Placement
4 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Oversubscribed $175 Million Private Placement
6 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
6 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
6 months ago - By: Zacks Investment Research
- Mentions:
OCS
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
6 months ago - By: Zacks Investment Research
- Mentions:
ARQT
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Reports Full Year 2024 Operating and Financial Results
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO to Participate in Upcoming Investor Conferences
7 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Reports Full Year 2024 Operating and Financial Results
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO to Participate in Upcoming Investor Conferences
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
a year ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
a year ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
9 months ago - By: SAB Biotherapeutics, Inc.
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Please enable JavaScript to continue using this application.